ABSTRACT
Background: There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens. Methods: This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses. Anti-RBD antibodies level and neutralising titres (NT50) against G614, Beta, Mu, Delta and Omicron variants were analysed. Reactogenicity was also assessed. Findings: 130 participants (TG:92; CG:38) completed standard vaccination. In TG, median (IQR) of anti-RBD antibodies after first BNT162b2 dose were 10740·0 BAU/mL (4466·0-12500) compared to 29·8 BAU/mL (14·5-47·8) in CG (p <0·0001). Median NT50 (IQR) of G614 was 2674·0 (1865·0-3997·0) in TG and 63·0 (16·0-123·1) in CG (p <0·0001). After second BNT162b2 dose, anti-RBD levels increased to ≥12500 BAU/mL (11625·0-12500) in TG compared to 1859·0 BAU/mL (915·4-3820·0) in CG (p <0·0001). NT50 was 2626·5 (1756·0-5472·0) and 850·4 (525·1-1608·0), respectively (p <0·0001). Variant-specific (Beta, Mu, Omicron) response was also assessed. Most frequent adverse reactions were headache, myalgia, and local pain. No severe AEs were reported. Interpretation: Heterologous BNT162b2 as third and fourth doses in previously suboptimal immunized individuals elicit stronger immune response than that obtained with two doses of BNT162b2. This apparent benefit was also observed in variant-specific response. No safety concerns arose. Funding: Partly funded by the Institute of Health Carlos-III and COVID-19 Fund, co-financed by the European Regional Development Fund (FEDER) "A way to make Europe".
ABSTRACT
Background: The COVID-19 outbreak has made funders, researchers and publishers agree to have research publications, as well as other research outputs, such as data, become openly available. In this extraordinary research context of the SARS CoV-2 pandemic, publishers are announcing that their coronavirus-related articles will be made immediately accessible in appropriate open repositories, like PubMed Central, agreeing upon funders' and researchers' instigation. Methods: This work uses Unpaywall, OpenRefine and PubMed to analyse the level of openness of articles about COVID-19, published during the first quarter of 2020. It also analyses Open Access (OA) articles published about previous coronavirus (SARS CoV-1 and MERS CoV) as a means of comparison. Results: A total of 5,611 COVID-19-related articles were analysed from PubMed. This is a much higher amount for a period of 4 months compared to those found for SARS CoV-1 and MERS during the first year of their first outbreaks (335 and 116 articles, respectively). Regarding the levels of openness, 88.8% of the SARS CoV-2 papers are freely available; similar rates were found for the other coronaviruses. Deeper analysis showed that (i) 67.4% of articles belong to an undefined Bronze category; (ii) 76.4% of all OA papers don't carry any license, followed by 10.4% which display restricted licensing. These patterns were found to be repeated in the three most frequent publishers: Elsevier, Springer and Wiley. Conclusions: Our results suggest that, although scientific production is much higher than during previous epidemics and is open, there is a caveat to this opening, characterized by the absence of fundamental elements and values ââon which Open Science is based, such as licensing.
Subject(s)
Access to Information , Coronavirus Infections , Pandemics , Pneumonia, Viral , PubMed , Publications/trends , Betacoronavirus , COVID-19 , Humans , SARS-CoV-2ABSTRACT
Introducción: Presentamos un estudio caso-control de tumores no definitorios de sida (TNDS) en una cohorte de pacientes infectados por el VIH en la que valoramos las tasas de incidencia, supervivencia y factores pronósticos de mortalidad. Métodos: Se recogieron de forma prospectiva en 7 hospitales, los diagnósticos de TNDS realizados de 2007 a 2011, con seguimiento posterior hasta diciembre de 2013. Se seleccionaron de forma aleatoria un grupo control de 221 pacientes VIH sin diagnóstico de cáncer. Resultados: Se diagnosticaron 221 TNDS en una cohorte inicial de 7.067 pacientes VIH. Los más frecuentes: hepatocarcinoma 20,5%, pulmón 18,7%, cabeza y cuello 11,9% y anal 10,5%. La tasa de incidencia de desarrollo de TNDS fue de 7,84/1.000 pacientes-año. Además de la edad y el tabaco, el tiempo en TAR (OR 1,11; IC 95% 1,05-1,17) y el uso de IP (OR 1,72; IC 95% 1,0-2,96) aumentaron el riesgo de desarrollar un TNDS. Durante el seguimiento fallecieron el 53,42%, con una mediana de supervivencia de 199,5 días. En el análisis de los factores pronósticos de mortalidad, los valores bajos de CD4 en el momento del diagnóstico del tumor (OR 0,99; IC 95% 0,99-1,0; p=0,033) y el diagnóstico previo de sida (OR 2,06; IC 95% 1,08-3,92) se asociaron con una mayor mortalidad. Conclusiones: Los predictores de TNDS en nuestra cohorte fueron la edad, el consumo de tabaco, los linfocitos CD4 y el mayor tiempo en TAR. La mortalidad es alta, siendo factores de riesgo los CD4 bajos en el momento del diagnóstico del TNDS y el diagnóstico previo de sida
Introduction: We present a case-control study of non-AIDS-defining cancers (NADCs) in a cohort of HIV-infected patients where we value the incidence, survival and prognostic factors of mortality. Methods: All NADCs diagnosis conducted from 2007 to 2011 in 7 hospitals were collected prospectively, with a subsequent follow up until December 2013. A control group of 221 HIV patients without a diagnosis of cancer was randomly selected. Results: Two hundred and twenty-one NADCs were diagnosed in an initial cohort of 7,067 HIV-infected patients. The most common were: hepatocellular carcinoma 20.5%, lung 18.7%, head and neck 11.9% and anal 10.5%. The incidence rate of NADCs development was 7.84/1,000 people-year. In addition to aging and smoking, time on ART (OR 1.11; 95% CI 1.05-1.17) and PI use (OR 1.72; 95% CI 1.0-2.96) increased the risk of developing a NADC. During follow-up 53.42% died, with a median survival time of 199.5 days. In the analysis of the prognostic factors of mortality the low values of CD4 at tumour diagnosis (OR 0.99; 95% CI 0.99-1.0; P=.033), and the previous diagnosis of AIDS (OR 2.06; 95% CI 1.08-3.92) were associated with higher mortality. Conclusions: Predictors of NADCs in our cohort were age, smoking, CD4 lymphocytes and time on ART. Mortality is high, with NADC risk factors being low CD4 count and previous diagnosis of AIDS
Subject(s)
Humans , Male , Female , Adolescent , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , HIV Infections/complications , Neoplasms/epidemiology , Neoplasms/mortality , Cohort Studies , Prospective Studies , Spain/epidemiology , Risk Factors , Prognosis , Tobacco Use Disorder/complicationsABSTRACT
INTRODUCTION: We present a case-control study of non-AIDS-defining cancers (NADCs) in a cohort of HIV-infected patients where we value the incidence, survival and prognostic factors of mortality. METHODS: All NADCs diagnosis conducted from 2007 to 2011 in 7 hospitals were collected prospectively, with a subsequent follow up until December 2013. A control group of 221 HIV patients without a diagnosis of cancer was randomly selected. RESULTS: Two hundred and twenty-one NADCs were diagnosed in an initial cohort of 7,067 HIV-infected patients. The most common were: hepatocellular carcinoma 20.5%, lung 18.7%, head and neck 11.9% and anal 10.5%. The incidence rate of NADCs development was 7.84/1,000 people-year. In addition to aging and smoking, time on ART (OR 1.11; 95% CI 1.05-1.17) and PI use (OR 1.72; 95% CI 1.0-2.96) increased the risk of developing a NADC. During follow-up 53.42% died, with a median survival time of 199.5 days. In the analysis of the prognostic factors of mortality the low values of CD4 at tumour diagnosis (OR 0.99; 95% CI 0.99-1.0; P=.033), and the previous diagnosis of AIDS (OR 2.06; 95% CI 1.08-3.92) were associated with higher mortality. CONCLUSIONS: Predictors of NADCs in our cohort were age, smoking, CD4 lymphocytes and time on ART. Mortality is high, with NADC risk factors being low CD4 count and previous diagnosis of AIDS.
Subject(s)
HIV Infections/complications , Neoplasms/complications , Neoplasms/epidemiology , Adult , Case-Control Studies , Female , Humans , Incidence , Male , Middle Aged , Prognosis , Prospective Studies , Risk Factors , Survival RateABSTRACT
Despite the huge advance that antiretroviral therapy represents for the prognosis of infection by the human immunodeficiency virus (HIV), opportunistic infections (OIs) continue to be a cause of morbidity and mortality in HIV-infected patients. OIs often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an OI. The present article updates our previous guidelines on the prevention and treatment of various OIs in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome
A pesar del gran avance que ha supuesto el tratamiento antirretroviral (TAR) para el pronóstico de la infección por el VIH, las infecciones oportunistas (IO) continúan siendo causa de morbilidad y mortalidad en estos pacientes. Ello ocurre en muchos casos debido a la inmunodepresión grave, bien ante la falta de adherencia al TAR, el fracaso del mismo o el desconocimiento de la existencia de la infección por el VIH en pacientes que comienzan con una IO. El presente artículo actualiza las recomendaciones de prevención y tratamiento de diferentes infecciones en pacientes con infección por VIH: parasitarias, fúngicas, víricas, micobacterianas, bacterianas e importadas, además del síndrome de reconstitución inmune
Subject(s)
Humans , HIV Infections/complications , AIDS-Related Opportunistic Infections/prevention & control , Anti-Retroviral Agents/therapeutic use , Evaluation of Results of Preventive Actions , Coinfection/epidemiology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/drug therapy , Practice Patterns, Physicians'ABSTRACT
Opportunistic infections continue to be a cause of morbidity and mortality in HIV-infected patients. They often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an opportunistic infection. The present article is an executive summary of the document that updates the previous recommendations on the prevention and treatment of opportunistic infections in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome. This document is intended for all professionals who work in clinical practice in the field of HIV infection
Las infecciones oportunistas siguen siendo una causa importante de morbi mortalidad en pacientes con infección por VIH. Ello ocurre en muchos casos debido a la inmunodepresión grave, bien ante la falta de adherencia al tratamiento antirretroviral, el fracaso del mismo o el desconocimiento de la existencia de la infección por el VIH en pacientes que comienzan con una infección oportunista. Este artículo es un resumen del documento de consenso que actualiza las recomendaciones previas de GESIDA respecto a la prevención y el tratamiento de las diferentes infecciones oportunistas en pacientes infectados por VIH: parasitarias, fúngicas, víricas, micobacterianas, bacterianas e importadas, además del síndrome de reconstitución inmune. Está dirigido a los profesionales que trabajan en la práctica clínica en el campo del VIH, con el objetivo de facilitarles una atención de calidad en la prevención y tratamiento de estas infecciones
Subject(s)
Humans , HIV Infections/complications , AIDS-Related Opportunistic Infections/prevention & control , Anti-Retroviral Agents/therapeutic use , Coinfection/epidemiology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/drug therapy , Practice Patterns, Physicians'ABSTRACT
Opportunistic infections continue to be a cause of morbidity and mortality in HIV-infected patients. They often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an opportunistic infection. The present article is an executive summary of the document that updates the previous recommendations on the prevention and treatment of opportunistic infections in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome. This document is intended for all professionals who work in clinical practice in the field of HIV infection.
Subject(s)
HIV Infections/complications , Opportunistic Infections/drug therapy , Opportunistic Infections/prevention & control , AIDS-Related Opportunistic Infections/prevention & control , Bacterial Infections/drug therapy , Bacterial Infections/prevention & control , Coinfection/drug therapy , Coinfection/prevention & control , Humans , Immune Reconstitution Inflammatory Syndrome/diagnosis , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/prevention & control , Mycoses/drug therapy , Mycoses/prevention & control , Parasitic Diseases/drug therapy , Parasitic Diseases/prevention & control , Virus Diseases/drug therapy , Virus Diseases/prevention & controlABSTRACT
Despite the huge advance that antiretroviral therapy represents for the prognosis of infection by the human immunodeficiency virus (HIV), opportunistic infections (OIs) continue to be a cause of morbidity and mortality in HIV-infected patients. OIs often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an OI. The present article updates our previous guidelines on the prevention and treatment of various OIs in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome.
Subject(s)
HIV Infections/complications , Opportunistic Infections/drug therapy , Opportunistic Infections/prevention & control , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/prevention & control , Antiretroviral Therapy, Highly Active , Bacterial Infections/drug therapy , Coinfection , Humans , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/prevention & control , Mycobacterium Infections/drug therapy , Mycobacterium Infections/prevention & control , Mycoses/drug therapy , Mycoses/prevention & control , Opportunistic Infections/etiology , Parasitic Diseases/drug therapy , Parasitic Diseases/prevention & control , Virus Diseases/drug therapy , Virus Diseases/prevention & controlABSTRACT
BACKGROUND: It is unknown whether a Toxoplasma gondii-specific T cell response is restored after successful combined antiretroviral therapy (cART) in patients with AIDS and current or previous toxoplasmic encephalitis (TE). METHODS: We performed a multicenter cross-sectional study with 17 healthy T. gondii-positive human immunodeficiency virus (HIV)-1-uninfected individuals and 90 patients coinfected with HIV-1 and T. gondii distributed in 5 groups according to their CD4(+) T cell counts and T. gondii infection (with or without current or previous TE). We investigated the lymphocyte proliferative response (LPR) and interferon (IFN)-γ production in response to T. gondii soluble antigen extract (SATg) and as CD4(+) and CD8(+) T cell subsets. RESULTS: SATg-specific LPR and IFN-γ production were not observed in many of the most immunosuppressed patients (CD4(+) T cell count, <200 cells/µL, with or without current or previous TE). By contrast, these responses occurred in a considerable percentage (LPR, 43%; IFN-γ production, 80%) of patients receiving successful cART (CD4(+) T cell count, >200 cells/µL) who presented with TE and had already stopped secondary TE prophylaxis. Similar results were found in immunocompetent asymptomatic patients who did not receive TE prophylaxis. The predictors of SATg-specific T cell responses and IFN-γ production were a cART-mediated increase in CD4(+) T cell count and LPR to phytohemagglutinin and viral suppression and a decrease in the activated (CD38(+)) CD8(+) T cell count, respectively. CONCLUSIONS: cART restores T. gondii-specific CD4 T cell responses in most patients with AIDS who had previous TE. Our data support the safety of withdrawing TE prophylaxis when the CD4(+) T cell count returns to levels >200 cells/µL.
Subject(s)
Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active , T-Lymphocyte Subsets/immunology , Toxoplasma/immunology , Toxoplasmosis, Cerebral/immunology , Acquired Immunodeficiency Syndrome/immunology , Adult , Antigens, Protozoan/immunology , CD4 Lymphocyte Count , Cell Proliferation , Cross-Sectional Studies , Female , Humans , Interferon-gamma/metabolism , Male , Middle AgedABSTRACT
Late diagnosis of HIV-1 infection is quite frequent in Western countries. Very few randomized clinical trials to determine the best antiretroviral treatment in patients with advanced HIV-1 infection have been performed. To compare immune reconstitution in two groups of very immunosuppressed (less than 100 CD4(+) cells/microl), antiretroviral-naive HIV-1-infected adults, 65 patients were randomly assigned in a 1:1 ratio to receive zidovudine + lamivudine + efavirenz (group A, 34 patients) or zidovudine + lamivudine + ritonavir-boosted indinavir (group B, 31 patients). The median (interquartile range) CD4(+) cell increase after 12 and 36 months was +199 (101, 258) and +299 (170, 464) cells/microl in the efavirenz arm and +136 (57, 235) and +228 (119, 465) cells/microl in the ritonavir-boosted indinavir arm (p > 0.05 for all time points). The proportion (95% confidence interval) of patients achieving HIV-1 RNA levels under 50 copies/ml was significantly greater in the efavirenz arm at 3 years by the intention-to-treat analysis [59% (41%, 75%) vs. 23% (10%, 41%)], whereas no differences were found in the on-treatment analysis. Immune activation (CD8(+)CD38(+) and CD8(+)CD38DR(+) T cells) was significantly lower for the efavirenz arm from month 6 to month 24. Adverse events were more frequent in the ritonavir-boosted indinavir arm. Almost all cases of disease progression and death were observed in the first year of treatment, with no significant differences between the two arms (p = 0.79 by the log-rank test). At 1 and 3 years, the immune reconstitution induced by an efavirenz-based regimen in very immunosuppressed patients was at least as potent as that induced by a ritonavir-boosted protease inhibitor-based antiretroviral regimen.
Subject(s)
Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , HIV Protease Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/administration & dosage , Adult , Aged , CD4 Lymphocyte Count , CD8-Positive T-Lymphocytes/immunology , Female , HIV Infections/immunology , HIV Infections/virology , HIV-1/isolation & purification , Humans , Male , Middle Aged , RNA, Viral/blood , Treatment Outcome , Viral LoadABSTRACT
La disciplina de enfermedades infecciosas es reconocidacomo especialidad clínica en la práctica totalidad de lospaíses de la Unión Europea, así como en los EE. UU.,Canadá y la mayoría de los países hispanoamericanos.Aunque los planes de formación en los distintos paíseseuropeos son heterogéneos, la Sección de EnfermedadesInfecciosas de la Unión Europea de EspecialidadesMédicas (UEMS) trabaja para su armonización.El European Board in Infectious Diseases, que datade 1998, recomienda una duración total del período deespecialización de 6 años, similar al de otrasespecialidades médicas (2 años de formación troncal y 4 deformación especializada). La actividad asistencial enenfermedades infecciosas en los hospitales de los distintospaíses se asemeja, en cuanto a cartera de servicios, a laque existe en los centros españoles. En este artículo serevisan los programas formativos, la actividad asistencial yla actividad científica en la disciplina de enfermedadesinfecciosas en los distintos países(AU)
Infectious Diseases is a recognised clinical specialty inalmost all European countries, in the United States ofAmerica, Canada and most countries in Central and SouthAmerica. Even though the training programs areheterogeneous in the different European countries, theInfectious Diseases section of the UEMS (European Unionof Medical Specialties) is working to harmonise them. In1998, the European Board of Infectious Diseasesrecommended a 6-year training period, similar to that ofother medical specialties, including 2 years of generalinternal medicine training and 2 years of specific training.The clinical activity and services provided by Infectious Diseases units in Spanish hospitals is similar to that inother countries. In this article, training programs, clinicalactivity and scientific activities in Infectious Diseases in thedifferent countries is reviewed(AU)
Subject(s)
Humans , Communicable Diseases/epidemiology , Medicine/trends , Infectious Disease Medicine , Americas/epidemiology , Europe/epidemiology , Education, Medical/trends , Societies, Medical/trends , Serial Publications/trends , Certification/trendsABSTRACT
La disciplina de enfermedades infecciosas es reconocidacomo especialidad clínica en la práctica totalidad de lospaíses de la Unión Europea, así como en los EE. UU.,Canadá y la mayoría de los países hispanoamericanos.Aunque los planes de formación en los distintos paíseseuropeos son heterogéneos, la Sección de EnfermedadesInfecciosas de la Unión Europea de EspecialidadesMédicas (UEMS) trabaja para su armonización.El European Board in Infectious Diseases, que datade 1998, recomienda una duración total del período deespecialización de 6 años, similar al de otrasespecialidades médicas (2 años de formación troncal y 4 de formación especializada). La actividad asistencial enenfermedades infecciosas en los hospitales de los distintos países se asemeja, en cuanto a cartera de servicios, a la que existe en los centros españoles. En este artículo se revisan los programas formativos, la actividad asistencial y la actividad científica en la disciplina de enfermedades infecciosas en los distintos países
Infectious Diseases is a recognised clinical specialty inalmost all European countries, in the United States ofAmerica, Canada and most countries in Central and SouthAmerica. Even though the training programs areheterogeneous in the different European countries, theInfectious Diseases section of the UEMS (European Unionof Medical Specialties) is working to harmonise them. In1998, the European Board of Infectious Diseasesrecommended a 6-year training period, similar to that ofother medical specialties, including 2 years of generalinternal medicine training and 2 years of specific training. The clinical activity and services provided by Infectious Diseases units in Spanish hospitals is similar to that in other countries. In this article, training programs, clinical activity and scientific activities in Infectious Diseases in thedifferent countries is reviewed
Subject(s)
Humans , Infectious Disease Medicine , Communicable Diseases/epidemiology , European Union , Americas , Medicine/trends , Periodicals as Topic , Education, Medical/trendsABSTRACT
BACKGROUND: Within the Multicenter Project on Tuberculosis Research performed in Spain in 1996-1997, the Bajo Deba Area reported the highest incidence of tuberculosis in the Basque Country. We analyzed the clinical and epidemiological characteristics of the tuberculosis population diagnosed in our area during the period of 1995 to 2006. METHODS: Ambispective, observational study. RESULTS: A total of 584 patients were diagnosed with tuberculosis. The disease affected the respiratory tract in 509 cases and other sites in 75 cases. The mean annual incidence rate of tuberculosis was 64.5 cases per 100 000 inhabitants (91.6 in 1995-1998; 34.9 in 2003-2006). The mean annual incidence rate of smear-positive patients was 20.7 cases per 100 000 inhabitants (33.8 in 1995-1998; 12.9 in 2003-2006). The 15 to 24-year-old group was the most highly affected during the period of 1995 to 1998 (mean annual incidence rate 199.4 cases per 100 000); in contrast, the > 75-year-old group was the most highly affected during the period of 2003 to 2006 (121.1 cases per 100 000 inhabitants). Fifty-three patients were co-infected by HIV (9%) (yearly mean of 11.6% in 1995-1998 and 7% in 2003-2006). Löwenstein culture was positive in 431 cases (73.8%). Resistance to isoniazid was detected in 1.4% out of a total of 287 strains tested, and multidrug resistance was not observed. Nine patients were immigrants (1.5%). Treatment completion was greater in our area (505 patients, 86.4%), as compared to that recorded in the Guipuzcoa province during the same period (1956 of 2525 patients, 77.5%) (P < .01). CONCLUSIONS: The Bajo Deba Area presented a high incidence of tuberculosis in the 1995 to 2006 period. Epidemiological trends showed a progressive decrease in the number of tuberculosis patients, with a shift from younger to older persons as the most highly affected age group. The impact of drug resistance and immigration was negligible on tuberculosis rates. The percentage of microbiologically confirmed cases was high. Treatment completion was satisfactory.
Subject(s)
Tuberculosis/epidemiology , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged , Prospective Studies , Retrospective Studies , Spain/epidemiologyABSTRACT
Introducción. La comarca del Bajo Deba comunicó la incidencia más elevada de la comunidad autónoma vasca en el Proyecto Multicéntrico de Investigación en Tuberculosis (PMIT) realizado en España en 1996-1997. Analizamos las características clínicas y epidemiológicas de la población tuberculosa diagnosticada en nuestra comarca en el período en estudio. Métodos. Estudio ambispectivo observacional. Resultados. Se han diagnosticado 584 pacientes; 509 casos han sido de localización respiratoria, y 75 casos, extrarrespiratorios. La tasa media de incidencia por año ha sido 64,5 casos por 100.000 habitantes (91,6 en 1995-1998; 34,9 en 2003-2006). La tasa media de casos bacilíferos ha sido 20,7 por 100.000 y año (33,8 en 1995-1998; 12,9 en 2003-2006). El grupo etario más afectado en el cuatrienio 1995-1998 fue el de 15-24 años (tasa de incidencia media de 199,4 casos por 100.000 y por año); en 2003-2006 lo ha sido el de mayores de 75 años (121,1 casos por 100.000 y por año). Se hallaban coinfectados por el VIH 53 pacientes (9%) (porcentaje medio anual del 11,6% en 1995-1998; el 7% en 2003-2006). Se ha obtenido un cultivo de Löwenstein positivo en 431 pacientes (73,8%). La resistencia a isoniacida ha sido del 1,4% de entre 287 cepas analizadas y no se ha detectado multirresistencia. Nueve pacientes eran inmigrantes (1,5%). El cumplimiento del tratamiento en el Bajo Deba en el período 1995-2006 ha sido satisfactorio en 505 pacientes (86,4%), mientras en la provincia de Guipúzcoa lo era en 1.956 de 2.525 pacientes diagnosticados y tratados en el mismo lapso de tiempo (77,5%) (p < 0,01). Conclusiones. La comarca del Bajo Deba presenta una alta incidencia de tuberculosis en el período estudiado. La evolución epidemiológica ha sido positiva con disminución de la incidencia de tuberculosis, de la contagiosidad, de la coinfección por el virus de la inmunodeficiencia humana (VIH), y con desplazamiento de las mayores tasas de enfermedad desde los grupos jóvenes a la tercera edad. La resistencia a tuberculostáticos y la inmigración no han tenido un papel determinante en la epidemiología. El porcentaje de casos confirmados microbiológicamente ha sido alto y el cumplimiento del tratamiento, satisfactorio (AU)
Within the Multicenter Project on Tuberculosis Research performed in Spain in 1996-1997, the Bajo Deba Area reported the highest incidence of tuberculosis in the Basque Country. We analyzed the clinical and epidemiological characteristics of the tuberculosis population diagnosed in our area during the period of 1995 to 2006. Methods. Ambispective, observational study. Results. A total of 584 patients were diagnosed with tuberculosis. The disease affected the respiratory tract in 509 cases and other sites in 75 cases. The mean annual incidence rate of tuberculosis was 64.5 cases per 100 000 inhabitants (91.6 in 1995-1998; 34.9 in 2003-2006). The mean annual incidence rate of smear-positive patients was 20.7 cases per 100 000 inhabitants (33.8 in 1995-1998; 12.9 in 2003-2006). The 15 to 24-year-old group was the most highly affected during the period of 1995 to 1998 (mean annual incidence rate 199.4 cases per 100 000); in contrast, the > 75-year-old group was the most highly affected during the period of 2003 to 2006 (121.1 cases per 100 000 inhabitants). Fifty-three patients were co-infected by HIV (9%) (yearly mean of 11.6% in 1995-1998 and 7% in 2003-2006). Löwenstein culture was positive in 431 cases (73.8%). Resistance to isoniazid was detected in 1.4% out of a total of 287 strains tested, and multidrug resistance was not observed. Nine patients were immigrants (1.5%). Treatment completion was greater in our area (505 patients, 86.4%), as compared to that recorded in the Guipuzcoa province during the same period (1956 of 2525 patients, 77.5%) (P <.01). Conclusions. The Bajo Deba Area presented a high incidence of tuberculosis in the 1995 to 2006 period. Epidemiological trends showed a progressive decrease in the number of tuberculosis patients, with a shift from younger to older persons as the most highly affected age group. The impact of drug resistance and immigration was negligible on tuberculosis rates. The percentage of microbiologically confirmed cases was high. Treatment completion was satisfactory (AU)
Subject(s)
Humans , Tuberculosis/epidemiology , Cohort Studies , AIDS-Related Opportunistic Infections/epidemiology , HIV Infections/epidemiology , Age DistributionABSTRACT
Infectious Diseases is a recognised clinical specialty in almost all European countries, in the United States of America, Canada and most countries in Central and South America. Even though the training programs are heterogeneous in the different European countries, the Infectious Diseases section of the UEMS (European Union of Medical Specialties) is working to harmonise them. In 1998, the European Board of Infectious Diseases recommended a 6-year training period, similar to that of other medical specialties, including 2 years of general internal medicine training and 2 years of specific training. The clinical activity and services provided by Infectious Diseases units in Spanish hospitals is similar to that in other countries. In this article, training programs, clinical activity and scientific activities in Infectious Diseases in the different countries is reviewed.
Subject(s)
Infectious Disease Medicine , Canada , Certification/standards , Curriculum , Education, Medical, Graduate/organization & administration , Education, Medical, Graduate/standards , Europe , Health Surveys , Hospital Departments/statistics & numerical data , Infectious Disease Medicine/education , Infectious Disease Medicine/organization & administration , Infectious Disease Medicine/trends , Latin America , Research Personnel/education , Research Personnel/standards , Societies, Medical , United StatesABSTRACT
OBJECTIVE: To evaluate the effectiveness and tolerability of a simplification regimen with tenofovir DF (TDF), lamivudine (3TC), and efavirenz (EFV) in HAART-experienced HIV-1-infected subjects with sustained viral suppression. METHOD: Patients with HIV-1 RNA <200 copies/mL during the previous 6 months and who switched their current twice-daily or three-times-daily HAART to a simplified once-daily regimen of TDF (300 mg), 3TC (300 mg), and EFV (600 mg) were included. RESULTS: 154 patients (70% males, mean age 42 years) were included. Previous HAART included a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen in 55% of the patients and a thymidine analog in 87%. The percentage of patients with viral load <200 copies/mL in the intent-to-treat (ITT) data set was 83% at 6 months and 75% at 12 months (98% and 96%, respectively, in the on-treatment [OT] analysis). Five patients (3%) were identified as virologic failures according to the study protocol. The mean CD4 T-cell count increased significantly 12 months after simplification (from 570 to 632 cells/mm3; p < .01). At 12 months, mean triglyceride levels decreased from 233 to 170 mg/dL (p < .01) and mean cholesterol levels decreased from 205 to 189 mg/dL (p < .01). Thirty-three patients (21%) discontinued the study treatment prior to completing the 12-month follow-up. CONCLUSION: Simplification to a once-daily regimen containing TDF, 3TC, and EFV is virologically and immunologically effective, well-tolerated, and safe with benefits in the lipid profile in the majority of patients.
Subject(s)
Adenine/analogs & derivatives , Anti-HIV Agents/administration & dosage , Benzoxazines/administration & dosage , HIV Infections/drug therapy , Lamivudine/administration & dosage , Organophosphonates/administration & dosage , Viral Load , Adenine/administration & dosage , Adenine/adverse effects , Adult , Alkynes , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active , Benzoxazines/adverse effects , CD4 Lymphocyte Count , Cholesterol/blood , Cyclopropanes , Female , HIV Infections/immunology , HIV Infections/virology , Humans , Lamivudine/adverse effects , Male , Middle Aged , Organophosphonates/adverse effects , Patient Acceptance of Health Care , RNA, Viral/blood , Tenofovir , Treatment Outcome , Treatment Refusal , Triglycerides/bloodABSTRACT
We present two cases of P. falciparum malaria in visitors to tourist resorts on the East Coast of the Dominican Republic, traditionally believed to be an area without risk of malaria. In both patients the malaria was severe (with 20% parasitization in one) and there was a long interval between the onset of symptoms and diagnosis. These cases are possibly related (along with a further 17 reports by the Centers for Disease Control and Prevention) to an increase in the population of Anopheles sp as a consequence of increased rainfall and floods provoked by a hurricane in September 2004, as well as to the presence of a semi-immune population (Haitian immigrants working in the construction and tourist sectors). Both physicians and patients should be aware of this outbreak so that adequate precautions can be taken and early diagnoses can be made.
Subject(s)
Malaria, Falciparum/diagnosis , Plasmodium falciparum/isolation & purification , Adult , Animals , Antimalarials/therapeutic use , Dominican Republic , Female , Humans , Malaria, Falciparum/drug therapy , Male , Middle Aged , TravelABSTRACT
Se presentan 2 casos de paludismo por Plasmodium falciparum en viajeros a centros turísticos de la costa este de República Dominicana, considerados clásicamente como libres de riesgo de paludismo. En ambos casos, se trató de pacientes con paludismo grave (con una parasitación del 20% en uno de ellos), con un tiempo largo entre el inicio de la sintomatología y el diagnóstico. Es posible que estos casos (junto con otros 17 comunicados por los Center for Disease Control and Prevention [CDC]) estén relacionados con un aumento en la población de Anopheles sp. como consecuencia del aumento de lluvias e inundaciones provocados por el paso de un huracán en septiembre de 2004, junto con la existencia de población semiinmune (inmigrantes haitianos trabajando en la construcción y el sector turístico). Es muy importante que tanto los médicos como los pacientes sean conscientes de este brote para facilitar la toma adecuada de precauciones y un diagnóstico precoz (AU)
We present two cases of P. falciparum malaria in visitors to tourist resorts on the East Coast of the Dominican Republic, traditionally believed to be an area without risk of malaria. In both patients the malaria was severe (with 20% parasitization in one) and there was a long interval between the onset of symptoms and diagnosis. These cases are possibly related (along with a further 17 reports by the Centers for Disease Control and Prevention) to an increase in the population of Anopheles sp as a consequence of increased rainfall and floods provoked by a hurricane in September 2004, as well as to the presence of a semi-immune population (Haitian immigrants working in the construction and tourists sectors). Both physicians and patients should be aware of this outbreak so that adequate precautions can be taken and early diagnoses can be made (AU)
Subject(s)
Male , Female , Adult , Middle Aged , Humans , Plasmodium falciparum/pathogenicity , Malaria, Falciparum/diagnosis , Malaria, Falciparum/epidemiology , Dominican Republic/epidemiologyABSTRACT
OBJECTIVE: This consensus document is an update of antiretroviral therapy (ART) recommendations for adult patients infected with the human immunodeficiency virus (HIV). METHODS: To formulate these recommendations, a panel composed of members of the Grupo de Estudio de Sida (GESIDA; AIDS Study Group) and the Plan Nacional sobre el Sida (PNS; Spanish AIDS Plan) reviewed the advances in current understanding of the pathophysiology of HIV, the safety and efficacy findings from clinical trials, and the results from cohort and pharmacokinetic studies published in biomedical journals or presented at scientific meetings over the last years. Three levels of evidence were defined according to the source of the data: randomized studies (level A), cohort or case-control studies (level B), and expert opinion (level C). The decision to recommend, consider or not recommend ART was established in each of these situations. RESULTS: ART consisting of at least three drugs is currently the initial treatment of choice for chronic HIV infection. These regimens should include 2 NRTI + 1 NNRTI or 2 NRTI + 1 PI. Initiation of ART is recommended in patients with symptomatic HIV infection. In asymptomatic patients, initiation of ART is recommended on the basis of CD4+ lymphocyte counts per L and plasma viral load, as follows: 1) Therapy should be started in patients with CD4+ counts of < 200 cells/microL; 2) Therapy should be started in most patients with CD4+ counts of 200-350 cells/microL, although it can be delayed when CD4+ count persists at around 350 cells/microL and viral load is low; and 3) Initiation of therapy can be delayed in patients with CD4+ counts of > 350 cells/microL. The initial objective of ART is to achieve an undetectable viral load. Adherence to therapy plays an essential role in maintaining the antiviral response. Because of the development of cross resistance, therapeutic options are limited when ART fails. Genotype studies are useful in these cases. Toxicity is a limiting factor in the use of ART, although the benefits outweigh the risks. In addition, the criteria for the use of ART are discussed in situations of acute infection, pregnancy, and post-exposure prophylaxis, and in the management of co-infection of HIV with HCV or HBV. CONCLUSIONS: CD4+ lymphocyte count is the most important reference factor for initiating ART in asymptomatic patients. The large number of available drugs, the increased sensitivity of tests to monitor viral load, and the possibility to determine viral resistance is leading to a more individualized approach to therapy.